Cartalax Research: Cartilage Bioregulator and Chondrocyte Biology

Cartalax (Ala-Glu-Asp-Leu) is a synthetic tetrapeptide bioregulator derived from cartilage tissue, developed by Vladimir Khavinson at the Saint Petersburg Institute of Bioregulation and Gerontology as part of his systematic tissue-specific peptide bioregulator programme. Sharing the Ala-Glu-Asp core sequence with pineal Epithalon (Ala-Glu-Asp-Gly), Cartalax targets musculoskeletal and cartilage biology through the proposed epigenetic bioregulator mechanism.

Structural Context

Cartalax (Ala-Glu-Asp-Leu) differs from Epithalon (Ala-Glu-Asp-Gly) only at the C-terminal position — leucine versus glycine. This minimal structural difference is proposed in Khavinson's bioregulator framework to confer tissue-targeting specificity: the Ala-Glu-Asp core provides the shared epigenetic pharmacophore, while the C-terminal residue directs the bioregulator toward specific tissue chromatin. For Cartalax, leucine at position 4 is proposed to direct activity toward cartilage and connective tissue gene regulatory elements, while glycine at position 4 in Epithalon directs activity toward pineal tissue.

This one-residue difference makes Cartalax and Epithalon ideal research pair for investigating the tissue-specificity hypothesis of Khavinson bioregulators. Running both compounds in parallel in chondrocyte versus pinealocyte cell models at matched molar concentrations provides direct data on whether the C-terminal residue determines tissue-specific gene regulatory effects as proposed — or whether the Ala-Glu-Asp core produces similar effects regardless of C-terminal identity.

Chondrocyte Biology and Osteoarthritis Research

Primary chondrocyte isolation: Articular cartilage from the femoral condyles of bovine knee joints (obtained from abattoir) provides abundant primary chondrocytes for research. Mince cartilage, wash three times in PBS, then digest sequentially with Pronase (0.1%, 37°C, 1 hour) followed by collagenase type II (0.2%, 37°C, 12-16 hours) with gentle agitation. Filter through 70µm cell strainer. Wash cells and plate at 100,000 cells/cm2 in DMEM + 10% FBS + 50µg/mL ascorbate.

Inflammatory challenge model: Add IL-1beta (10ng/mL) to chondrocyte cultures for 24 hours to establish the catabolic OA phenotype. Then treat with Cartalax (1nM-10µM) for 48-72 hours while maintaining IL-1beta. Measure: COL2A1 (type II collagen gene) and ACAN (aggrecan gene) by RT-PCR for anabolic matrix synthesis; MMP-13 (collagenase-3) and ADAMTS-5 (aggrecanase-2) by RT-PCR and activity assay for catabolic enzyme suppression; SOX9 (master chondrocyte transcription factor) by Western blot; and IL-6, COX-2 as inflammatory markers.

Human osteoarthritic chondrocytes: Cartilage from total knee replacement surgery (with appropriate ethics approval and patient consent) provides OA chondrocytes that already exhibit the disease phenotype without exogenous IL-1beta stimulation. OA chondrocytes show elevated MMP-13, reduced COL2A1 and ACAN, elevated COX-2 and iNOS — a baseline catabolic phenotype that makes them a more clinically relevant model than normal chondrocytes with exogenous inflammatory challenge.

3D Cartilage Research Models

Two-dimensional chondrocyte monolayer culture does not maintain the rounded chondrocyte morphology or the high-proteoglycan environment of native cartilage. Three-dimensional culture systems better recapitulate cartilage biology and provide more predictive data.

Agarose encapsulation: Dissolve low-melting-point agarose at 4% w/v in PBS, cool to 37°C. Mix 1:1 with chondrocyte suspension at 40×10^6 cells/mL (final: 2% agarose, 20×10^6 cells/mL). Cast in 5mm diameter cylindrical moulds, allow gelation at room temperature. Transfer to culture medium with Cartalax supplementation. Incubate 21-42 days with medium changes every 2-3 days. At endpoint: hydroxyproline assay (total collagen content), dimethylmethylene blue (DMMB) colorimetric assay (glycosaminoglycan content), histology (Safranin-O/Fast Green, type II collagen IHC), and biomechanical testing (confined compression or dynamic mechanical analysis).

Fibrin hydrogel: Mix fibrinogen (20mg/mL in TBS) with chondrocytes, then add thrombin (2 U/mL) to initiate gelation. Culture in chondrogenic medium (DMEM-HG, 10ng/mL TGF-beta3, 100nM dexamethasone, 50µg/mL ascorbate, 40µg/mL L-proline) with and without Cartalax supplementation. TGF-beta3 at sub-maximal concentrations allows detection of Cartalax-mediated potentiation.

Key Published Research

• Khavinson VKh, et al. "Peptide bioregulators of tissue-specific functions." Saint Petersburg Institute of Bioregulation and Gerontology, 2003.
• Khavinson V, et al. "Short peptides stimulate genome expression." Advances in Gerontology, 2013.
• Anisimov VN, Khavinson VKh. "Peptide bioregulation of aging: results and prospects." Biogerontology, 2010. PMID: 20490741

View Cartalax →

For laboratory and analytical research purposes only. Not for human or veterinary use.